SCHEMBL9230265

SCHEMBL9230265

CNc1c(F)ccc(OC)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 4/20 0.38
▸ GAA P10253 3/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ PDE4D Q08499 1/20 0.36
▸ HTR2A P28223 2/20 0.36
▸ HTR2C P28335 2/20 0.36
▸ HTR2B P41595 2/20 0.36
▸ LMNA P02545 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ RET P07949 1/20 0.35
▸ KIF5B P33176 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23962788 0.83 HTR2A (0.39) TUBB1GAAMAPK1KMT2ASMN1; SMN2
SCHEMBL625995 0.80 IDO1 (0.41) TUBB1GAAMAPK1KMT2ASMN1; SMN2
SCHEMBL18970429 0.80 HTR2A (0.39) MAPK1KMT2ASMN1; SMN2HTR2AHTR2C
SCHEMBL6137822 0.77 CES2 (0.32) —
SCHEMBL9285762 0.75 NFE2L2 (0.44) GAAMAPK1KMT2ASMN1; SMN2PDE4D
SCHEMBL802723 0.75 HTR2A (0.44) TUBB1MAPK1HTR2AHTR2CHTR2B
SCHEMBL4410380 0.74 TUBB1 (0.41) TUBB1GAAMAPK1PDE4D
SCHEMBL28696000 0.74 MEP1B (0.37) MAPK1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5511699 0.74 TSHR (0.38) GAAKMT2A
SCHEMBL15682035 0.74 CA2 (0.47) TUBB1MAPK1LMNAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946266-B2 Substituted triazole and imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-02-03 — — US disclosed
US-8946266-B2 Substituted triazole and imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-02-03 — — US disclosed
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-05-31 — — US disclosed
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A TUBB1 2176/4885GAA 599/4885MAPK1 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback